1219 results about "Colitis" patented technology

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention relates to the technical field of functional microorganism screening and application, and particularly provides a strain of lactobacillus plantarum and an application of the lactobacillus plantarum in improvement of intestinal inflammation and repair of intestinal mucosa injury. The plant lactobacillus is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) on August 1, 2024, the address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the plant lactobacillus is CGMCC No.31521. The strain has remarkable antioxidant, bacteriostatic and anti-inflammatory effects, can repair intestinal barrier injury of mice with colitis, promote renewal of intestinal stem cells, promote growth of intestinal beneficial bacteria and inhibit proliferation of harmful bacteria, can be widely applied to prevention and treatment of enteritis, and has a wide market prospect.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention discloses application of polygonatum kingianum polysaccharide in preparation of medicine for treating ulcerative colitis, and relates to the field of biomedicine.The preparation method of the polygonatum kingianum polysaccharide comprises the following steps that S1, polygonatum kingianum roots are taken, smashed and then screened, and polygonatum kingianum powder is prepared; s2, the polygonatum kingianum powder obtained in the step S1 is soaked in an ethanol solution, and polygonatum kingianum powder residues are obtained; s3, performing water extraction on the polygonatum kingianum powder residues obtained in the step S2 to obtain an extracting solution; s4, concentrating the extracting solution obtained in the step S3, adding ethanol into the concentrated solution to precipitate polysaccharide, and centrifugally separating to obtain crude polysaccharide; the polygonatum kingianum polysaccharide disclosed by the invention is high in purity, the effectiveness of the polygonatum kingianum polysaccharide in treatment of ulcerative colitis is verified, and a new solution is provided for relieving the problem of shortage of current colitis treatment medicines.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.

The invention discloses a carrier-free nano-particle with pH / ROS dual response as well as a preparation method and application of the carrier-free nano-particle. The preparation method comprises the following steps: enabling quinolizidine alkaloid and flavonol to be subjected to self-assembly, so as to prepare quinolizidine alkaloid-flavonol carrier-free nano particles; modifying the quinolizidine alkaloid-flavonol carrier-free nano particles by adopting a phenylboronic acid-hyaluronic acid conjugate, so as to prepare nano particles modified by the phenylboronic acid-hyaluronic acid conjugate; and coating the surfaces of the nano-particles modified by the phenylboronic acid-hyaluronic acid conjugate with a pH sensitive polymer to prepare the pH / ROS dual-response carrier-free nano-particles. The sophocarpidine-kaempferol carrier-free nanoparticles with pH / ROS dual response, prepared by the invention, have the advantages of good targeting property, high biocompatibility, small toxicity and adverse reaction and the like, meanwhile, the nanoparticles have a good anti-inflammatory effect, and a new choice is provided for the treatment of ulcerative colitis.

The invention relates to the technical field of microbial medicines, and particularly discloses Brawler's bacteria EMF75-02B1B and an application of the Brawler's bacteria EMF75-02B1B. The invention discloses Blauria sp. EMF75-02B1B, which is preserved in the Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Blauria sp. EMF75-02B1B is GDMCC No: 65084. A mouse model proves that the Brawler bacteria EMF75-02B1B can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight loss and colon shortening degree of the ulcerative colitis mouse, enhance the intestinal barrier function and relieve inflammatory response.

The present invention provides an application of a thorn sugar neutral polysaccharide in preparing a drug for preventing and / or treating ulcerative colitis, and belongs to the field of medical technology. Animal experimental results show that after the thorn sugar neutral polysaccharide is used in a mouse model of ulcerative colitis, the phenomenon of colon shortening can be alleviated, the production of harmful bacteria can be inhibited, the abundance of Helicobacter genus can be reduced, the number of beneficial bacteria can be increased, and the abundance of Lactobacillus genus, Bacteroides genus and Oscillatory Spirochete genus can be increased. Therefore, the thorn sugar neutral polysaccharide of the present invention can be used as a drug for preparing a drug for preventing or treating ulcerative colitis.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The present invention relates to the technical field of probiotics, and in particular to a strain of Lactobacillus casei ZKLc1221, its lactobacillus and its application in improving ulcerative colitis. Lactobacillus casei )ZKLc1221 has been deposited in the General Microbiology Center of China Microorganism Culture Collection Committee on June 21, 2023, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 27673. The lactobacillus obtained by optimizing the fermentation conditions of Lactobacillus casei ZKLc1221 provided by the present invention has good thermal stability, good effect in improving ulcerative colitis, and can significantly improve pathological damage to the colon.

The invention discloses a Gegen Qinlian decoction vesicle-like nanoparticle as well as an extraction method and application thereof, and belongs to the technical field of biological medicines. The method comprises the following steps: preparing a radix puerariae qinlian decoction stock solution; placing at 4-8 DEG C for 12-15 hours to obtain a gelatinous substance; carrying out low-speed centrifugation at 4-8 DEG C, and taking supernate, so as to obtain crude extract of the vesicle-like nanoparticles of the radix puerariae, radix scutellariae and rhizoma coptidis decoction; carrying out ultracentrifugation at 4-8 DEG C, discarding the supernatant, and carrying out PBS resuspension precipitation to obtain a crude product of the vesicle-like nano-particles of the Gegen Qinlian decoction; and centrifuging 16000g at the temperature of 4-8 DEG C for 10-15 minutes, taking supernate, and filtering by using a 0.22 mu m filter membrane, so as to obtain the vesicle-like nanoparticles of the Gegen Qinlian decoction. According to the Gegen Qinlian decoction vesicle-like nanoparticles as well as the extraction method and the application thereof, the bioavailability and the targeting property of effective components in the Gegen Qinlian decoction are remarkably improved through a nanocrystallization technology, the concentration of the medicine at the ulcerative colitis part is enhanced, and the treatment effect is effectively improved.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

The present invention discloses a black chicken liver hydrolyzed peptide that can be used to improve ulcerative colitis, and its preparation method and application, which belong to the field of biomedicine technology. The preparation method of the black chicken liver hydrolyzed peptide comprises the following steps: making black chicken liver into minced meat and mixing it with water, heating the obtained liquid material, adding alkaline protease for enzymatic hydrolysis, inactivating the enzyme and collecting the supernatant by centrifugation, and freeze-drying to obtain the black chicken liver hydrolyzed peptide. The present invention adopts formaldehyde titration to detect the degree of hydrolysis, adopts SDS-PAGE electrophoresis and Tricine-SDS-PAGE electrophoresis to detect the molecular weight, performs sequence analysis by LC-MS / MS, uses a database to predict the biological function of peptide segments, detects the antioxidant and blood pressure lowering ability of black chicken liver peptide by in vitro experiments, and detects the effect of black chicken liver peptide in improving colitis by mouse experiments. The results show that the black chicken liver peptide prepared by the present invention has the advantages of antioxidant, blood pressure lowering and improvement of ulcerative colitis.

The invention belongs to the technical field of medical auxiliary diagnosis, and discloses an ulcerative colitis virtual biopsy method and system based on a multi-modal image, and the method comprises the steps: building an ulcerative colitis medical image database; constructing a prediction data set according to the extracted quantitative features and the pathological grades of the ulcerative colitis patients; based on the prediction data set, constructing and training an ulcerative colitis virtual biopsy model; and acquiring new clinical data of a patient with ulcerative colitis in real time, inputting the acquired new clinical data into the trained ulcerative colitis virtual biopsy model, and outputting a pathological grading result of ulcerative colitis through extraction and prediction of pathological features. According to the method, automatic analysis of image and endoscopic image features of the lesion area can be realized, the pathological activity state of the ulcerative colitis patient can be accurately judged, and association with long-term prognosis of the patient is established, so that help is provided for clinicians to formulate an individualized UC treatment scheme.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention belongs to the technical field of drug delivery, and particularly relates to a multi-response colitis disease targeting hydrogel microsphere as well as a preparation method and application thereof. The hydrogel microsphere comprises a calcium ion cross-linked sodium alginate microsphere and HA-Cys / Cur NPs which is encapsulated in the calcium ion cross-linked sodium alginate microsphere, the preparation method comprises the following steps: self-assembling cysteine ethyl ester modified hyaluronic acid and curcumin to form nano-particles, encapsulating HA-Cys / Cur NPs into sodium alginate microspheres by an emulsification method, and carrying out calcium ion crosslinking, so as to obtain the hydrogel. The hydrogel microspheres have pH and GSH response characteristics and hyaluronic acid-mediated active targeting capability, are stable in a gastric acid environment, are accurately released at a colon part and target macrophages at an inflammation part, and NPs disconnects disulfide bonds and releases curcumin in an intracellular high GSH environment, so that synergistic treatment of anti-inflammation, anti-oxidation and intestinal mucosa repair is realized, and the curative effect is good. The medicine has a good application prospect in treatment of ulcerative colitis.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention relates to the technical field of microbial medicines, and in particular discloses a doer's bacterium EMF18-06B1D and an application of the doer's bacterium EMF18-06B1D. The invention relates to a Dorenia phocaeensis EMF18-06B1D, which is preserved in Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Dorenia phocaeensis EMF18-06B1D is GDMCC No: 65085. The invention further discloses a preparation method of the Dorenia phocaeensis EMF18-06B1D. A mouse model proves that the polythermia EMF18-06B1D can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight reduction trend and the colon shortening degree of the ulcerative colitis mouse, and contribute to intestinal barrier function recovery and intestinal inflammatory response reduction.

The invention discloses bifidobacterium lactis BA-C44 and application of the bifidobacterium lactis BA-C44 in relieving ulcerative colitis symptoms, the bifidobacterium lactis BA-C44 is preserved in the China Center for Type Culture Collection on December 04, 2023, and the preservation number is CCTCC NO: M 2023447. A product prepared from the bifidobacterium lactis BA-C44 disclosed by the invention has the beneficial effect of relieving symptoms of ulcerative colitis. Besides, the bifidobacterium lactis BA-C44 has good temperature tolerance and gastrointestinal fluid tolerance, is convenient for storage of commercial products after preparation, is easier to survive in intestines and stomach, and achieves the purpose of relieving symptoms of ulcerative colitis, so that the bifidobacterium lactis BA-C44 has a good application prospect.

The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention provides a nano preparation for breaking oxidative stress-inflammation vicious circle and regulating intestinal flora as well as a preparation method and application of the nano preparation. The preparation method of the preparation comprises the following steps: dissolving potassium ferricyanide and polyvinylpyrrolidone in a solution, slowly dropwise adding a zinc acetate dihydrate solution into the solution, stirring, standing, and repeatedly performing ultrafiltration centrifugal washing to obtain zinc-doped Prussian blue; crushing the yeast cells to obtain yeast cell walls; the yeast cell wall and the zinc-doped Prussian blue are repeatedly co-extruded through a liposome extruder to obtain the nano preparation. The ZnPBA in the nano material can efficiently remove active oxygen at an inflammation part and reduce secretion of inflammatory factors, and the oxidative stress-inflammatory vicious circle of ulcerative colitis is broken; meanwhile, the YCW can deliver the ZnPBA to an inflammation part in a targeted manner to kill pathogenic escherichia coli, and mannose components can promote growth of probiotics to realize bidirectional regulation of intestinal flora. The material is simple in preparation method, can be synthesized on a large scale and is used for treating ulcerative colitis.

The invention discloses an anus medicine applying and applying device suitable for local treatment of ulcerative colitis, relates to the field of medical instruments, and solves the problem that an existing anus medicine applying device is difficult to operate. The anus medicine applying and applying device comprises a device shell and an injection tube installed at the end of the device shell, and a holding cylinder is arranged on the outer side of the device shell; a rubber piston is mounted on the inner side of the device shell in a sliding manner; the dosing mechanism is used for improving the medicine applying convenience of the injection tube, and the dosing mechanism is installed between the device shell and the holding cylinder; through the administration mechanism, a pushing rubber piston can be pushed to be arranged on the outer side of the device shell, so that an L-shaped structure is formed between the device shell and the holding cylinder, a patient can conveniently insert an injector into the anus with a single hand, the device is convenient for patients with more body types to use, the problem that a traditional medicine applying device is difficult to operate is solved, the pain of the patient in medicine applying is relieved, and the patient experience is improved. Therefore, the convenience of applying medicine to the anus is improved.